This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

2B3-301

BBB Therapeutics B.V.

Drug Names(s): Glutathione PEGylated Lipidic Cyclosporin A, NVP014

Description: 2B3-301, a glutathione PEGylated lipidic cyclosporin A, has been shown to possess neuroprotective properties utilizing the Company's proprietary G-Technology delivery system.

Deal Structure: In September 2014, to-BBB announced significant additions to complete its new management team as well as changing its name from to-BBB technologies B.V. to BBB Therapeutics B.V.

to-BBB and NeuroVive
In October 2010, NeuroVive and to-BBB are entering into a joint program to develop therapies for stroke and other acute neurodegenerative diseases by combining their technologies. NeuroVive is funding the initial development up to preclinical Proof of Concept, after which the two companies have agreed to develop and commercialize the product jointly.

Partners: NeuroVive Pharmaceutical AB


2B3-301 News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

[Request a Free Demo] [Subscriber Login] [Search for another drug]